Thursday 15 September 2016

£16m funding awarded to Newcastle Biomedical Research Centre

More than £16m funding awarded for ground-breaking North East medical research after the NIHR Newcastle Biomedical Research Centre (BRC) was renewed for a further five years.

The National Institute for Health Research (NIHR), which is funded through the Department for Health, today announced that the Newcastle BRC was one of 20 successful BRCs throughout England to receive funding for 2017 to 2022 following a competitive bidding process worth a record £816m.

The further funding awarded to Newcastle’s Biomedical Research Centre will support Research Themes including dementia, liver disease, musculoskeletal disease, neuromuscular disease, skin and oral disease.

The NIHR Newcastle Biomedical Research Centre is a partnership between Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, working together under the umbrella of the Newcastle Academic Health Partners, delivering a programme of research to improve the prevention, diagnosis and treatment of major common diseases affecting the older population.

Professor Avan Sayer, Director, NIHR Newcastle Biomedical Research Centre & Professor of Geriatric Medicine said: “We are delighted with this latest NIHR Biomedical Research Centre award – our third successful application in this national competition.

“It will provide exceptional opportunities for our early translational research and, excitingly, we will also be able to apply our expertise in long-term conditions to improve the health of growing numbers of older people with ageing syndromes such as sarcopenia – the loss of muscle mass and strength, and frailty.”

A University and NHS partnership

Sir Leonard Fenwick, Chief Executive for the Newcastle upon Tyne Hospitals NHS Foundation Trust added: “We are very pleased to learn that Newcastle’s Biomedical Research Centre has been awarded ongoing NIHR funding, allowing us to continue to deliver world class translational research into ageing and long-term conditions.

“We very much see this as a clear mandate to advance our internationally recognised expertise in Lewy Body dementia, liver disease, musculoskeletal disease and neuromuscular disease, as well as skin and oral disease.”

The UK is already a world leader in pioneering medical breakthroughs and this record investment will ensure this strong tradition continues. It is estimated that for every £1 the Department of Health invests, hospitals/universities will generate £6 – from public funders of research, charities and industry partners – a boost for the economy.